(Currently under development)
An innovative solution for sustained drug delivery
DebioSTARTM is an innovative implantable drug delivery technology for the sustained delivery of pharmaceutical compounds.
By use of a perfectly controlled nanoporous membrane, the drug can be delivered from an implantable system over several weeks to several months. The delivery profile can be tailored to specific pharmacokinetic requirements by modification of the size as well as the thickness of the membrane. Additional surface chemistry can be added to the membrane in order to delay the delivery over a prolonged period of time.
The membrane is fully biocompatible and can be used for a long term, allowing its use in "refillable" as well as "single use" implantable systems.
The DebioSTARTM technology is intended to be used for local drug delivery as well as systemic drug delivery (subcutaneous, intra-peritoneal or intra-muscular).
The unique characteristics of the nanoporous membrane are based on a novel and patented manufacturing process. Such membrane can incorporate highly controlled pores of as small as one nanometre size, up to 250 nanometres. All pores are almost identical and highly controlled in size and dimensions.
The number of pores can be as high as one billion pores/cm2. The thickness of the membrane can be between 50 nanometres and several hundreds of micrometres.
Testing of the membrane with different drugs has already shown a very linear release from several days to several months, in vitro.
DebioSTARTM can be used as a passive device as well as an active pressurized system (e.g. osmotic pressure).
The intent of Debiotech is to propose this innovative technology to pharmaceutical companies to offer a new range of therapeutic options, thereby increasing the efficacy and/or convenience of continuous therapy regimens. The first candidates are peptides, hormones, anti-cancer drugs, NSAI and CNS drugs.
Debiotech S.A., Av. de Sévelin 28, 1004 Lausanne, Switzerland.
© Copyright Debiotech S.A. all rights reserved.